Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Aquestive Therapeutics (AQST)
NASDAQ:AQST
RESEARCH TOOLSreports
Holding AQST?
Track your performance easily
AQST Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.86 - $6.23
Previous Close$3.65
Volume1.35M
Average Volume (3M)1.51M
Market Cap
$332.80M
Enterprise Value$278.45M
Total Cash (Recent Filing)$77.89M
Total Debt (Recent Filing)$24.45M
Price to Earnings (P/E)―
Beta0.97
Next Earnings
Mar 11, 2025EPS Estimate
-$0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.45
Shares Outstanding91,178,193
10 Day Avg. Volume2,499,814
30 Day Avg. Volume1,513,568
Standard Deviation0.31
R-Squared0.20
Alpha0.00238
Financial Highlights & Ratios
Price to Book (P/B)-7.30
Price to Sales (P/S)5.65
Price to Cash Flow (P/CF)-7.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.73
Enterprise Value/Gross Profit9.36
Enterprise Value/Ebitda-15.90
Forecast
1Y Price Target
$11.20Price Target Upside206.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Aquestive Therapeutics News
PremiumCompany Announcements
Aquestive Therapeutics Gains FDA Support for Anaphylm
PremiumCompany Announcements
Aquestive Therapeutics Announces Board and Committee Changes
PremiumCompany Announcements
Aquestive Therapeutics Advances Drug Candidates Amid Challenges
PremiumCompany Announcements
Aquestive Therapeutics: Progress in Drug Innovation
Bulls Say, Bears Say
Bulls Say
FDA FeedbackAnaphylm pre-NDA feedback from the FDA is clear, and reinforces de-risked path to approval.
Market ExclusivityLibervant receives Orphan Drug exclusivity in very young children, extending market exclusivity in this segment to 2031.
Regulatory ApprovalLibervant is the first and only FDA approved orally administered rescue product for the treatment of seizure clusters in patients with epilepsy between two and five years of age.
Bears Say
Market CompetitionThere is a risk of the Suboxone franchise facing quicker-than-expected competition from generics.
Product Launch DelaysLibervant's market introduction in the U.S. may face delays, impacting its market penetration and success.
Regulatory ChallengesThe FDA highlighted concerns over data adequacy and lower effectiveness in certain study arms for Anaphylm.
---
Ownership Overview
14.95% Insiders
8.61% Mutual Funds
25.15% Other Institutional Investors
41.97% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AQST FAQ
What was Aquestive Therapeutics’s price range in the past 12 months?
Aquestive Therapeutics lowest stock price was $1.86 and its highest was $6.23 in the past 12 months.
What is Aquestive Therapeutics’s market cap?
Currently, no data Available
When is Aquestive Therapeutics’s upcoming earnings report date?
Aquestive Therapeutics’s upcoming earnings report date is Mar 11, 2025 which is in 79 days.
How were Aquestive Therapeutics’s earnings last quarter?
Aquestive Therapeutics released its earnings results on Nov 04, 2024. The company reported -$0.13 earnings per share for the quarter, missing the consensus estimate of -$0.118 by -$0.012.
Is Aquestive Therapeutics overvalued?
According to Wall Street analysts Aquestive Therapeutics’s price is currently Undervalued.
Does Aquestive Therapeutics pay dividends?
Aquestive Therapeutics does not currently pay dividends.
What is Aquestive Therapeutics’s EPS estimate?
Aquestive Therapeutics’s EPS estimate is -$0.13.
How many shares outstanding does Aquestive Therapeutics have?
Aquestive Therapeutics has 91,178,190 shares outstanding.
What happened to Aquestive Therapeutics’s price movement after its last earnings report?
Aquestive Therapeutics reported an EPS of -$0.13 in its last earnings report, missing expectations of -$0.118. Following the earnings report the stock price went down -7.573%.
Which hedge fund is a major shareholder of Aquestive Therapeutics?
Among the largest hedge funds holding Aquestive Therapeutics’s share is Woodline Partners LP. It holds Aquestive Therapeutics’s shares valued at 4M.
---
Aquestive Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.20 (206.85% Upside)
$11.20 (206.85% Upside)
Blogger Sentiment
Bullish
AQST Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 247.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $213.8 over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.4%
Last 30 Days ▼ 0.6%
Last 30 Days ▼ 0.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
95.18%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
84.97%
Trailing 12-Months
Company Description
Aquestive Therapeutics
Aquestive Therapeutics, Inc. is a specialty pharmaceutical company focused on identifying, developing, and commercializing differentiated products to address unmet medical needs. The company has a late-stage proprietary product pipeline focused on the treatment of Central nervous system (CNS) diseases, as well as orally-administered complex molecules that can be alternatives to invasively-administered standard of care therapies. Its product candidates include Libervant, Sympazan, and AQST-117 (Riluzole). Aquestive Therapeutics develops and delivers drugs via its PharmFilm® technology. The firm also collaborates with pharmaceutical partners to bring new molecules to market in differentiated and highly-marketable dosage forms. In addition to its proprietary product candidates, the company, with its partners, has a portfolio of development-stage products and commercialized products, such as Suboxone, a prescription medicine for the treatment of opioid dependence. The company was founded in January 2004 and is headquartered in Warren, NJ.
---
AQST Company Deck
---
AQST Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in product development and market access, with positive clinical study outcomes and expanded commercial capabilities. However, financial challenges were evident with increased net losses and higher expenses.Read More>---
AQST Stock 12 Month Forecast
Average Price Target
$11.20
▲(206.85% Upside)
Technical Analysis
Avadel Pharmaceuticals
―
Karyopharm Therapeutics
―
EyePoint Pharmaceuticals
―
Verastem
―
Best Analysts Covering AQST
1 Year
1 Year Success Rate
11/17 ratings generated profit
1 Year Average Return
+63.45%
reiterated a buy rating 2 days ago
Copying Ram Selvaraju's trades and holding each position for 1 Year would result in 64.71% of your transactions generating a profit, with an average return of +63.45% per trade.
---